Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EBT (2021 - 2025)

Amylyx Pharmaceuticals has reported EBT over the past 5 years, most recently at $111.6 million for Q4 2025.

  • Quarterly results put EBT at $111.6 million for Q4 2025, down 57.65% from a year ago — trailing twelve months through Dec 2025 was -$112000.0 (up 70.45% YoY), and the annual figure for FY2025 was -$112000.0, up 70.45%.
  • EBT for Q4 2025 was $111.6 million at Amylyx Pharmaceuticals, up from -$34.4 million in the prior quarter.
  • Over the last five years, EBT for AMLX hit a ceiling of $263.6 million in Q4 2024 and a floor of -$118.6 million in Q1 2024.
  • Median EBT over the past 5 years was -$25.7 million (2021), compared with a mean of -$1.6 million.
  • Peak annual rise in EBT hit 3970.04% in 2024, while the deepest fall reached 8549.82% in 2024.
  • Amylyx Pharmaceuticals' EBT stood at -$28.3 million in 2021, then soared by 652.95% to $156.6 million in 2022, then plummeted by 95.86% to $6.5 million in 2023, then soared by 3970.04% to $263.6 million in 2024, then tumbled by 57.65% to $111.6 million in 2025.
  • The last three reported values for EBT were $111.6 million (Q4 2025), -$34.4 million (Q3 2025), and -$41.4 million (Q2 2025) per Business Quant data.